Developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease
About
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue and provides a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intra-operative imaging based on its pH-sensitive micelle technology.
pH is an indicator for several diseases including cancer, Alzheimer’s and metabolic disorders. By targeting pH, a clear delineation between diseased and healthy tissue can be digitalized to develop a broad range of targeted applications. OncoNano's platform is an ultra-pH-sensitive drug delivery vehicle (micelle) that has a digital ON-OFF response to pH changes: it switches ON in the more acidic environment of cells and stays OFF in normal cells. Conjugating these micelles with fluorescent probes provides sharp diagnostic or intraoperative tumor imaging at low doses. At high doses, the same micelles serve to alter the metabolism pathways and buffer the lysosomal pH in cancer cells, providing therapeutic benefit.
Leadership
Management
Ravi Srinivasan, Ph.D.
Founder, President and CEO
Matthew Head
Chief Financial Officer
Yalia Jayalakshmi, Ph.D.
Vice President, Clinical Development
Don Kruppa
Vice President, Operations
Kathy Rath
Vice President, Regulatory Affairs
Tian Zhao, Ph.D.
Director of Research & Development
Board of Directors
Al Guillem, Ph.D.
Chairman of the Board, Former President of ZS Pharma, Inc.
Ravi Srinivasan, Ph.D.
Founder, President and CEO of OncoNano Medicine
John Dyett
Founder and Managing Director of Salem Partners, LLC
Paritosh Dhawale, Ph.D.
General Manager of Contrast Media at GE Healthcare
Joydeep Goswami, Ph.D.
President, Clinical NGS and Oncology at Thermo Fisher Scientific
News
PRESS RELEASES
Publications
April 2017 – Advanced Drug Delivery Reviews
Investigation of endosome and lysosome biology by ultra pH-sensitive nanoprobes
December 2016 – Nature Biomedical Engineering
A transistor-like pH nanoprobe for tumour detection and image-guided surgery
November 2016 – Advanced Materials
Digitization of endocytic pH by hybrid ultra-pH-sensitive nanoprobes at single-organelle resolution
October 2016 – Nature Communications
Molecular basis of cooperativity in pH-triggered supramolecular self-assembly
OncoNano Medicine Inc. complies with the EU-U.S. Privacy Shield Framework as set forth by the U.S. Department of Commerce regarding the collection, use, and retention of personal information transferred from the European Union to the United States. OncoNano Medicine Inc. has certified to the Department of Commerce that it adheres to the Privacy Shield Principles. If there is any conflict between the terms in this privacy policy and the Privacy Shield Principles, the Privacy Shield Principles shall govern. To learn more about the Privacy Shield program, and to view our certification, please visit https://www.privacyshield.gov/.